Advertisement

Topics

BioSyent’s Share Price Drops on Q3 Earnings

18:30 EST 21 Nov 2018 | Investing News Network

Rene Geohrum, CEO of BioSyent, said the decrease in international revenue was the result of “restrictions in a particular export market.”

Related Biotechnology, Pharmaceutical and Healthcare News

The post BioSyent’s Share Price Drops on Q3 Earnings appeared first on Investing News Network.

Original Article: BioSyent’s Share Price Drops on Q3 Earnings

NEXT ARTICLE

More From BioPortfolio on "BioSyent’s Share Price Drops on Q3 Earnings"

Advertisement

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here: Contact BioPortfolio.
All rights reserved. All other trademarks recognized. Copyright © 1997-2019 BioPortfolio Limited. Site developed by Alacrify Ltd.